Matthew J. Matasar, MD

Articles

Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy

December 10th 2024

Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.

Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL

June 13th 2024

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

BTK Degraders and Other Targets in Mantle Cell Lymphoma

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data

February 14th 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma

February 14th 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma

February 7th 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib

February 7th 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

January 31st 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL

January 31st 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

January 24th 2023

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

January 24th 2023

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

January 17th 2023

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.

Overview of Mantle Cell Lymphoma and First-Line Treatment Options

January 17th 2023

Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.

Dr. Matasar on the Unmet Needs of Immunotherapy for DLBCL

September 21st 2022

Matthew J. Matasar, MD, discusses the unmet needs remaining in diffuse large B-cell lymphoma.

Dr. Matasar on the Rationale for Combining Copanlisib and Rituximab in Indolent NHL

May 13th 2021

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

Dr. Matasar on the Design of the CHRONOS-3 Trial Examining Copanlisib/Rituximab in Indolent NHL

April 20th 2021

Matthew J. Matasar, MD, discusses the design of the phase 3 CHRONOS-3 trial in indolent non-Hodgkin lymphoma.

Dr. Matasar on the Efficacy of Copanlisib Plus Rituximab in Indolent NHL

April 14th 2021

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

July 14th 2017

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.